Corbus Pharmaceuticals Holdings Management

Management Kriterienprüfungen 4/4

Corbus Pharmaceuticals Holdings CEO ist Yuval Cohen , ernannt in Apr 2014, hat eine Amtszeit von 10.58 Jahren. Die jährliche Gesamtvergütung beträgt $1.14M , bestehend aus 52.6% Gehalt und 47.4% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.027% der Aktien des Unternehmens, im Wert von $54.77K . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 6.9 Jahre bzw. 5.1 Jahre.

Wichtige Informationen

Yuval Cohen

Geschäftsführender

US$1.1m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	52.6%
Amtszeit als Geschäftsführer	10.6yrs
Eigentum des Geschäftsführers	0.03%
Durchschnittliche Amtszeit des Managements	6.9yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	5.1yrs

Jüngste Management Updates

Recent updates

Corbus Pharmaceuticals' Sell-Off: Speculative Entry Price In Oncology And Obesity Therapies

Nov 11

Here's Why Shareholders Should Examine Corbus Pharmaceuticals Holdings, Inc.'s (NASDAQ:CRBP) CEO Compensation Package More Closely

Jun 12

Should Shareholders Reconsider Corbus Pharmaceuticals Holdings, Inc.'s (NASDAQ:CRBP) CEO Compensation Package?

May 14

What Kind Of Shareholders Hold The Majority In Corbus Pharmaceuticals Holdings, Inc.'s (NASDAQ:CRBP) Shares?

Mar 11

Is Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) Weighed On By Its Debt Load?

Feb 04

Corbus Pharmaceuticals: Down But Not Out

Jan 29

Have Insiders Been Buying Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Shares This Year?

Jan 09

Corbus's lenabasum shows benefit in autoimmune disorder

Nov 09

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Yuval Cohen im Vergleich zu den Einnahmen von Corbus Pharmaceuticals Holdings verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Sep 30 2024	n/a	n/a	-US$39m
Jun 30 2024	n/a	n/a	-US$35m
Mar 31 2024	n/a	n/a	-US$34m
Dec 31 2023	US$1m	US$599k	-US$45m
Sep 30 2023	n/a	n/a	-US$47m
Jun 30 2023	n/a	n/a	-US$46m
Mar 31 2023	n/a	n/a	-US$51m
Dec 31 2022	US$1m	US$598k	-US$42m
Sep 30 2022	n/a	n/a	-US$42m
Jun 30 2022	n/a	n/a	-US$35m
Mar 31 2022	n/a	n/a	-US$39m
Dec 31 2021	US$5m	US$579k	-US$46m
Sep 30 2021	n/a	n/a	-US$44m
Jun 30 2021	n/a	n/a	-US$77m
Mar 31 2021	n/a	n/a	-US$98m
Dec 31 2020	US$3m	US$559k	-US$111m
Sep 30 2020	n/a	n/a	-US$129m
Jun 30 2020	n/a	n/a	-US$115m
Mar 31 2020	n/a	n/a	-US$75m
Dec 31 2019	US$4m	US$559k	-US$71m
Sep 30 2019	n/a	n/a	-US$62m
Jun 30 2019	n/a	n/a	-US$56m
Mar 31 2019	n/a	n/a	-US$70m
Dec 31 2018	US$4m	US$540k	-US$56m
Sep 30 2018	n/a	n/a	-US$49m
Jun 30 2018	n/a	n/a	-US$41m
Mar 31 2018	n/a	n/a	-US$37m
Dec 31 2017	US$3m	US$463k	-US$32m

Vergütung im Vergleich zum Markt: YuvalDie Gesamtvergütung ($USD1.14M) liegt im Durchschnitt der Unternehmen ähnlicher Größe auf dem Markt US ($USD1.46M).

Entschädigung vs. Einkommen: YuvalDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.

Geschäftsführer

Yuval Cohen (49 yo)

10.6yrs

Amtszeit

US$1,137,622

Vergütung

Dr. Yuval Cohen, Ph.D. has been the Chief Executive Officer and Director at Corbus Pharmaceuticals Holdings, Inc. since April 11, 2014. Dr. Cohen served as Senior Vice President at Celsus Therapeutics Plc...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Yuval Cohen	CEO & Director	10.6yrs	US$1.14m	0.027% $ 54.8k
Sean Moran	Chief Financial Officer	10.6yrs	US$717.26k	0.069% $ 141.0k
Lindsey Smith	Head of Corporate Communications & Patient Advocacy	no data	keine Daten	keine Daten
Christina Bertsch	Vice President of Human Resources	3.3yrs	keine Daten	keine Daten
Dominic Smethurst	Chief Medical Officer	less than a year	keine Daten	keine Daten

6.9yrs

Durchschnittliche Betriebszugehörigkeit

50yo

Durchschnittliches Alter

Erfahrenes Management: CRBPDas Führungsteam des Unternehmens verfügt über eine langjährige Erfahrung (6.9 ).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Yuval Cohen	CEO & Director	10.6yrs	US$1.14m	0.027% $ 54.8k
Alan Holmer	Independent Chairman	10.8yrs	US$120.66k	0.025% $ 51.0k
Winston Kung	Director	less than a year	keine Daten	keine Daten
Anne Altmeyer	Independent Director	2.2yrs	US$90.51k	0% $ 0
John Jenkins	Independent Director	6.4yrs	US$109.74k	0.00027% $ 550.2
Yong Ben	Independent Director	1.7yrs	US$94.21k	0% $ 0
Rachelle Jacques	Independent Director	5.6yrs	US$104.42k	0% $ 0
Peter Salzmann	Independent Director	4.7yrs	US$89.41k	0% $ 0
Stephen Nishimura	Member of Scientific Advisory Board	no data	keine Daten	keine Daten

5.1yrs

Durchschnittliche Betriebszugehörigkeit

54.5yo

Durchschnittliches Alter

Erfahrener Vorstand: CRBPDie Vorstandsmitglieder gelten als erfahren (5.1 Jahre durchschnittliche Amtszeit).

Corbus Pharmaceuticals Holdings Management

Management Kriterienprüfungen 4/4

Wichtige Informationen

Jüngste Management Updates

Corbus Pharmaceuticals Holdings, Inc. Announces Board and Committee Changes

CEO & Director notifies of intention to sell stock

Corbus Pharmaceuticals Holdings, Inc., Annual General Meeting, May 16, 2024

Corbus Pharmaceuticals Holdings, Inc. Appoints Dominic Smethurst as Chief Medical Officer

Corbus Pharmaceuticals Holdings, Inc. Announces Resignation of Rachael Brake, Ph.D., as Chief Scientific Officer, Effective from February 19, 2024

Corbus Pharmaceuticals Holdings, Inc. Appoints Anne Altmeyer to Board of Directors

Recent updates

Corbus Pharmaceuticals' Sell-Off: Speculative Entry Price In Oncology And Obesity Therapies

Corbus Pharmaceuticals Holdings, Inc. Presents New CRB-913 Pre-Clinical Data At Obesity Week 2024

Corbus Pharmaceuticals Holdings, Inc. Announces Enrollment Completion of Dose Escalation Stage of Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC (CRB-701)

Price target decreased by 13% to US$71.00

New major risk - Share price stability

Corbus Pharmaceuticals Holdings, Inc. Announces Board and Committee Changes

CEO & Director notifies of intention to sell stock

Corbus Pharmaceuticals Holdings, Inc., Annual General Meeting, May 16, 2024

Corbus Pharmaceuticals Holdings, Inc. Announces Dosing of First Patient in U.S. Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC

Corbus Pharmaceuticals Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.

Corbus Pharmaceuticals Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.

New major risk - Negative shareholders equity

Corbus Pharmaceuticals Holdings, Inc. Appoints Dominic Smethurst as Chief Medical Officer

Corbus Pharmaceuticals Holdings, Inc. Announces Resignation of Rachael Brake, Ph.D., as Chief Scientific Officer, Effective from February 19, 2024

New major risk - Shareholder dilution

Corbus Pharmaceuticals Holdings, Inc. has completed a Follow-on Equity Offering in the amount of $82.175 million.

Corbus Pharmaceuticals Holdings, Inc. has completed a Follow-on Equity Offering in the amount of $82.175 million.

New major risk - Shareholder dilution

Corbus Pharmaceuticals Holdings, Inc. has completed a Follow-on Equity Offering.

Corbus: Ability To Have Best-In-Class Nectin-4 Targeting Drug

Corbus Pharmaceuticals Holdings, Inc. Announces Data from the First-in-Human Clinical Study of CRB-701 (SYS6002)

Nasdaq Gants Corbus Pharmaceuticals Holdings an Extension Until May 8, 2024 to Regain Compliance

Corbus Pharmaceuticals Receives Letter from Nasdaq Regarding Non-Compliance with the Minimum Stockholders’ Equity Requirement for Continued Listing on The Nasdaq Capital Market, Under Listing Rule 5550(b)(1)

New minor risk - Share price stability

Corbus Pharmaceuticals Holdings, Inc. Presents Results of Two Pre-Clinical Studies on its Anti-VETA>8 Monoclonal Antibody (CRB-601) at the 2023 SITC Annual Meeting

New minor risk - Shareholder dilution

Price target increased to US$2.20

Corbus Pharmaceuticals Holdings, Inc. Presents Latest Preclinical Data for CRB-601 at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

Corbus Pharmaceuticals Holdings, Inc. Appoints Anne Altmeyer to Board of Directors

First half 2022 earnings released

Corbus Pharmaceuticals GAAP EPS of -$0.11

Corbus Pharmaceuticals Holdings Gets a 180-Day Extension to January 2, 2023, to Regain Compliance with the Minimum Bid Price Requirement

Price target increased to US$2.20

Corbus Pharmaceuticals Holdings, Inc. Enters into a Binding Term Sheet with Venn Therapeutics, LLC, to Resolve the Claims by Venn Against the Corbus Pharmaceuticals Holdings, Inc

Corbus Pharmaceuticals Holdings, Inc. Announces That New Preclinical Data for CRB-601 Are Being Presented in an Oral Presentation At the New York Academy of Sciences Frontiers in Cancer Immunotherapy Conference in New York

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Corbus Pharmaceuticals Holdings, Inc., Annual General Meeting, May 18, 2022

Consensus forecasts updated

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to US$1.65

Corbus Pharmaceuticals Holdings Receives A Letter from the Listing Qualifications Staff of the Nasdaq Stock Market

Is Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) Using Too Much Debt?

Third quarter 2021 earnings released: US$0.017 loss per share (vs US$0.43 loss in 3Q 2020)

Head of Research & Chief Medical Officer Barbara White has left the company

Second quarter 2021 earnings released: US$0.15 loss per share (vs US$0.52 loss in 2Q 2020)

Consensus revenue estimates fall to US$2.32m

Corbus Pharmaceuticals Holdings, Inc.(NasdaqGM:CRBP) dropped from Russell 3000E Growth Index

Corbus Pharmaceuticals Announces Topline Results from Determine Phase 3 Study of Lenabasum for Treatment of Dermatomyositis

Here's Why Shareholders Should Examine Corbus Pharmaceuticals Holdings, Inc.'s (NASDAQ:CRBP) CEO Compensation Package More Closely

Corbus Pharmaceuticals Holdings, Inc. Announces Licensing Deals for Two New Monoclonal Antibodies, CRB-601 and CRB-602 to Further Expand Pipeline into Cancer and Fibrotic Diseases

First quarter 2021 earnings released: US$0.14 loss per share (vs US$0.43 loss in 1Q 2020)

Consensus revenue estimates increase to US$3.68m

Should Shareholders Reconsider Corbus Pharmaceuticals Holdings, Inc.'s (NASDAQ:CRBP) CEO Compensation Package?

Consensus forecasts updated

Full year 2020 earnings released: US$1.42 loss per share (vs US$1.12 loss in FY 2019)

Corbus Pharmaceuticals Holdings, Inc. Provides Clinical Program Updates

What Kind Of Shareholders Hold The Majority In Corbus Pharmaceuticals Holdings, Inc.'s (NASDAQ:CRBP) Shares?

Corbus Pharmaceuticals Holdings, Inc. to Report Q4, 2020 Results on Mar 15, 2021

Is Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) Weighed On By Its Debt Load?

New 90-day high: US$2.58

Corbus Pharmaceuticals: Down But Not Out

New 90-day high: US$1.61

Have Insiders Been Buying Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Shares This Year?

Price target lowered to US$1.88

Corbus Pharmaceuticals Holdings, Inc. Announces the Resignation of Robert Discordia as Chief Operating Officer

Corbus Pharmaceuticals Holdings, Inc. Presents Additional Data from RESOLVE-1 Study in Systemic Sclerosis

Corbus's lenabasum shows benefit in autoimmune disorder

Corbus Pharmaceuticals Holdings, Inc. to Report Q3, 2020 Results on Nov 10, 2020

Robert Discordia Will No Longer Serve as Chief Operating Officer of Corbus Pharmaceuticals Holdings, Inc